Zymeworks Inc.: FDA approval for Ziihera triggers target price increase to 55 USD and milestone payment
Reading Time: 3 minutes
The business model of Zymeworks Inc. (ZYME) combines internal research with strategic partners, relieving its own cost base. The US approval of the cancer drug Ziihera brings Zymeworks a contractually agreed one-time payment of 0.25 billion USD. After the approval, the analysis firm H.C. Wainwright raised the target price for the stock from 51 USD to 55 USD and confirmed its buy recommendation. Diversified biotech business model meets oncology growth trends The foundation of Zymeworks (ZYME) is based on the development of multifunctional biotherapeutics....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
